Observed performance metrics in laboratory models
Observed performance metrics in laboratory models
SR-9011 is typically administered at a dose of 10 mg once daily for research applications, with one capsule per 24 hours being the standard.
Consistency in dosing and alignment with structured protocols can support optimal research outcomes.
SR-9011 is typically administered at a dose of 10 mg once daily for research applications, with one capsule per 24 hours being the standard.
Consistency in dosing and alignment with structured protocols can support optimal research outcomes.
Free shipping worldwide on all orders. This includes delivery to APO, DPO & FPO addresses.
Domestic: 5-7 business days.
International: 10-14 business days.
No express shipping due to timing inconsistencies from couriers.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
Unordered list
Bold text
Emphasis
Superscript
Subscript
Research summary on SR-9011
SR-9011 is a synthetic small molecule that activates the nuclear receptors REV-ERBα and REV-ERBβ
SR-9011 is technically not a SARM — it is a Rev-ErbA agonist with similar effects to SR-9009.
In research settings, it has been shown to:
✔ Increase metabolic activity.
✔ Improve endurance.
✔ Support weight management.
⚡ METABOLIC BOOST:
Enhances mitochondrial activity and metabolic rate.
🏅 ATHLETIC PERFORMANCE:
Enhances muscle function and endurance in preclinical research.
📏️ BODY WEIGHT CONTROL:
Promotes fat utilization over carbohydrate reliance.
1. Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence
2. The Effect of Rev-erbα Agonist SR9011 on the Immune Response and Cell Metabolism of Microglia
https://doi.org/10.3389/fimmu.2020.550145
3. Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists
4. In-vitro metabolic studies of REV-ERB agonists SR9009 and SR9011
5. Anti-proliferative actions of a synthetic REV-ERBα/β agonist in breast cancer cells
https://www.sciencedirect.com/science/article/pii/S0006295215003263
Explore the best stack options.